^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAR260301

    i
    Associations
    News

    Trials

    Company:
    Sanofi
    Drug class:
    PI3K inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer (NCT01673737)
    Phase 1
    Sanofi
    Completed
    Last update posted :
    04/10/2015
    Initiation :
    08/01/2012
    Primary completion :
    02/01/2015
    Completion :
    02/01/2015
    BRAF
    |
    BRAF mutation
    |
    Zelboraf (vemurafenib) • SAR260301